The three‐point MACE was reduced by 13% in the liraglutide group, with a 22% reduction in CV death and a 15% reduction in total mortality. There was also a non‐significant numerical reduction in non‐fatal MI and non‐fatal stroke.74 The Kaplan–Meier curves for the three‐point MACE showed a separation of events between liraglutide‐ and placebo‐treated patients after 12 to 18 months, suggesting that the beneficial effect of liraglutide is not immediate and may be mediated by a reduction in atherosclerosis‐related events.suggesting that the beneficial effect of liraglutide is not immediate and may be mediated by a reduction in atherosclerosis‐related events.